Mizuho Bullish on Horizon Pharma (HZNP) Into Today's Investor Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Actimmune and Friedreich's Ataxia Could Help Horizon Pharma (HZNP) Post Upside, Mizuho Says; PT to $34
November 10, 2015 6:57 AM ESTHorizon Pharma (NASDAQ: HZNP) reported 3Q:15 revenue of $226.5M vs. consensus of $193.2M. Adjusted EPS of $0.70 also beat the consensus number of $0.41. The beat was driven by strong product demand (volumes) across all of the company's brands, coupled with lower than expected SG&A expense and... More
Horizon Pharma (HZNP) Tops Q3 EPS by 30c; Boosts FY15 Revenue Outlook
November 6, 2015 7:01 AM ESTHorizon Pharma (NASDAQ: HZNP) reported Q3 EPS of $0.70, $0.30 better than the analyst estimate of $0.40. Revenue for the quarter came in at $292.7 million versus the consensus estimate of $185.7 million.
Horizon Pharma sees FY2015 revenue of $750-760 million, versus prior guidance of $660-680 million and the... More
